EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
KNOWLEDGE BANK
-
Articles
Gene Therapy: Breakthrough Treatments for Rare Diseases
The idea of gene therapy is radically changing the sphere of medicine with the possibilities to cure the patients with the rare hereditary diseases These diseases which are usually brought about by the alteration of the sequence
Unveiling Opportunities: Trends and Analysis in the European Pharmaceutical Market
The European pharmaceutical market stands at the forefront of global healthcare playing a pivotal role in the development and distribution of lifesaving medications Renowned for its innovative research and commitment to healthcare excellence the industry is experiencing dynamic shifts that demand the unwavering attention of BB stakeholders With a profound emphasis on precision medicine digital hea...
From Molecule to Market: Building a Regulatory-Ready Manufacturing Strategy
Every pharmaceutical executive can recite the journey from molecule to market Far fewer can say with confidence at which point in that journey their manufacturing strategy became capable of withstanding a regulatory inspection The distinction matters more than it once did Approval timelines are compressing
Intelligent Collaborations: Navigating the Current Biopharma M&A Rebound
Biopharma MA didnt collapse in and it recalibrated Deal volumes softened valuations compressed and acquirers grew cautious as macroeconomic headwinds elevated interest rates and regulatory scrutiny made largescale consolidation feel riskier than it once had But the underlying drivers never went away They accumulated
The Top 15 Pharma Blogs and Publications in the World
To the extent that it is recognized as a vital source of information the pharmaceutical industry relies heavily on credible blogs and publications These platforms not only provide insights into the latest research and trends but also foster discussions that can influence policy and practice within the healthcare sector
Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics
People respond very differently to medications depending on their weight age inborn capability to metabolize drugs the individual characteristics of the disease or the presence of comorbidities The wellknown assumption that one size fits all has clearly revealed all its limitations and become questionable Notably among humans pediatric patients represent
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Unveiling Opportunities: Trends and Analysis in the European Pharmaceutical Market
Kate Williamson
The European pharmaceutical market is undergoing transformative shifts, marked by a biopharmaceutical boom, digital health integration, and precision medicine advancements. Stakeholders must navigate...
-
2
From Molecule to Market: Building a Regulatory-Ready Manufacturing Strategy
Lakshmi
Regulatory readiness is still treated by many pharmaceutical organisations as a late compliance exercise, bolted on once a molecule has been designed, scaled and transferred. That sequencing has becom...
-
3
Intelligent Collaborations: Navigating the Current Biopharma M&A Rebound
Doug Drysdale
The current biopharma M&A environment reflects a market under pressure from a $300 billion patent cliff, shifting regulatory conditions, and intensifying competition across novel modalities. This...
-
4
The Top 15 Pharma Blogs and Publications in the World
Kate Williamson
-
5
Mini-Tablets: A Valid Strategy to Combine Efficacy and Safety in Pediatrics
Guendalina Zuccari
Silvana Alfei
Danilo Marimpietri
Valentina Iurilli
Paola Barabino
Leonardo Marchitto
In the treatment of pediatric diseases, mass-produced dosage forms are often not suitable for children. Commercially available medicines are commonly manipulated and mixed with food by caregivers at h...
press releases Read more...
Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products
Biocodex an independent French pharmaceutical company announces a million investment to develop an industrial platform in Beauvais France dedicated to Live Biotherapeutic Products LBPs derived from the microbiome Building on more than years of expertise in living microorganisms microbiota fermenta...
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Boehringer Ingelheim headquartered in Germany and Sino Biopharmaceutical Limited HK together with its subsidiaries SBP Group today announced a strategic multiprogram option and license agreement to advance potential nextgeneration cancer treatments based on antibodydrug conjugate ADC and Tcell engag...
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Nxera Pharma Co Ltd announces that its subsidiary Nxera Pharma UK Ltd has entered into an exclusive global license agreement the Agreement with AbbVie Inc AbbVie for Nxeras EP agonist program including NXE a novel small molecule EP receptor agonist discovered
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Oryzon Genomics SA a clinicalstage biopharmaceutical company and global leader in epigenetics today announced that VIVALDI a Phase Ib pilot study sponsored by CETLAM Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplsicas has been authorized in Spain
Events Read more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
10 - 10
Nov 2026Women in AI
Real Chemistry, 2nd Floor, Lon...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 25
Nov 2026BioPharma Deals - The Survival Series
Munich, Germany
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
LATEST NEWS Read more...
Portal Innovations and Altitude Lab Partner to Strengthen Utah’s Life Sciences Startup Ecosystem
Portal Innovations a venture development platform supporting earlystage life sciences companies today announced a strategic partnership with Altitude Lab to strengthen the resources available to life sciences entrepreneurs in Salt Lake City Through the partnership Altitude Lab will relocate its acce...
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
MRM Health a clinicalstage biotech developing microbiomebased therapies for immunemediated diseases and Biocodex an independent French pharmaceutical company with more than years of experience in the microbiome field today announced the launch of a strategic partnership to establish specialized man...
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
Idorsia Ltd announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients to
Evestia Clinical Acquires Emtex Life Science to Further Enhance its Global Full-Service Clinical Research Capabilities
Evestia Clinical a leading independent global specialist Contract Research Organization CRO today announced the acquisition of Emtex Life Science Emtex a specialist regulatory medical writing company headquartered in Belgium The acquisition strengthens Evestia
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the first patient was dosed with UGN a nextgeneration investigational oncolytic virus The Phase trial will evaluate the safety tolera...
Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease
Graviton BioScience Corporation Graviton and CinRx Pharma CinRx today announced the formation of CinRock Pharma CinRock a jointly governed biopharmaceutical company established to accelerate the development of novel ROCKtargeted therapies for patients with cardiovascular diseases









